BioCardia (BCDA) Change in Receivables (2010 - 2025)
BioCardia's (BCDA) quarterly Change in Receivables came in at $20000.0 in Q4 2025, up 300.0% year-over-year from $5000.0 in Q4 2024, and up 300.0% quarter-over-quarter from -$10000.0 in Q3 2025.
Powered by 
Analysis
BioCardia (BCDA) Change in Receivables (2010 - 2025) Analysis & Trends
BioCardia (BCDA) has reported Change in Receivables for 14 consecutive years, with $20000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Change in Receivables rose 300.0% year-over-year to $20000.0 in Q4 2025; TTM through Dec 2025 was $20000.0, a 120.62% increase from a year earlier, with the FY2025 full-year figure at $20000.0, up 120.62% from the prior year.
- Change in Receivables was $20000.0 for Q4 2025 at BioCardia, up from -$10000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $179000.0 in Q1 2022 and troughed at -$115000.0 in Q2 2022.
- A 5-year average of -$13117.6 and a median of -$29000.0 in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 526.19% in 2022, down 394.87% in 2022.
- Over 5 years, Change in Receivables stood at -$51000.0 in 2021, then slumped by 94.12% to -$99000.0 in 2022, then soared by 70.71% to -$29000.0 in 2023, then surged by 65.52% to -$10000.0 in 2024, then surged by 300.0% to $20000.0 in 2025.
- The last three Change in Receivables figures came in at $20000.0 (Q4 2025), -$10000.0 (Q3 2025), and $10000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 11.97 Mn |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | 20.36 Mn |
| 4 | Legend Biotech | 3.56 Bn | 2.60 Bn | 251.50 Mn | 1.60 Mn |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | 45.46 Mn |
| 8 | Sarepta Therapeutics | 2.19 Bn | 1.40 Bn | 251.87 Mn | -17.99 Mn |
| 9 | Vericel | 1.96 Bn | 1.80 Bn | 56.40 Mn | 3.33 Mn |
| 10 | BioCardia | 13.18 Mn | 9.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Dec 31, 2024 | -10,000.00 |
| Jun 30, 2024 | -58,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | -29,000.00 |
| Jun 30, 2023 | -38,000.00 |
| Mar 31, 2023 | -48,000.00 |
| Dec 31, 2022 | -99,000.00 |
| Sep 30, 2022 | 89,000.00 |
| Jun 30, 2022 | -115,000.00 |
| Mar 31, 2022 | 179,000.00 |
| Dec 31, 2021 | -51,000.00 |
| Sep 30, 2021 | -31,000.00 |
| Jun 30, 2021 | 39,000.00 |
| Mar 31, 2021 | -42,000.00 |
| Dec 31, 2020 | -72,000.00 |
| Sep 30, 2020 | 90,000.00 |
| Jun 30, 2020 | 35,000.00 |